Inpharmatica Licenses Biopendium and Chematica to Schering
As BioInform reported in September [BioInform 09-29-05], Inpharmatica said last week that it has licensed its Biopendium and Chamatica technologies to Schering as part of a druggability assessment collaboration.
Inpharmatica said that Schering intends to use the technologies to support its protein-prioritization efforts.
The financial terms of the agreement were not disclosed.
Shimadzu to Distribute Phenomenome Discoveries' Metabolomics Software